2026-04-30T03:51:11Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/191102024-11-29T15:12:54Zcom_20.500.12105_2173com_20.500.12105_2051col_20.500.12105_19597

00925njm 22002777a 4500 dc Marión, Rosa M author Blasco, MA author 2017-04-28 Aging can be defined as the progressive loss of physiological integrity that leads to tissue dysfunction and increased risk for developing age-associated human pathologies, such as cancer, diabetes mellitus, cardiovascular disorders, and neurodegenerative diseases.(1) Therapeutic strategies to delay or prevent aging are aimed to decrease the deleterious effects of aging and to improve the quality of life in aged individuals and eventually to extend the human life span. In addition, deep molecular understanding of the mechanisms of aging may lead to new treatments for age-related diseases. In line with this, a recent article in Cell(2) shows that cyclic induction of Yamanaka reprogramming factors in vitro, what the authors called "partial reprogramming," reduces age-associated features in mouse and human cells. Strikingly, partial reprogramming induced in vivo in a mouse model of premature aging ameliorates some aging-associated hallmarks and extends their prematurely shortened life span. Importantly, these beneficial effects are not accompanied by dedifferentiation or loss of cellular identity. Finally, the authors show that partial in vivo reprogramming increases the regenerative capacity of physiologically aged wild-type mice. Circ Res . 2017 Apr ;120(9):1381-1383. 10.1161/CIRCRESAHA.117.310594 1524-4571 Circulation research 28450358 http://hdl.handle.net/20.500.12105/19110 Long Live Partial Reprogramming.